SCHEDULE 13G/A: BlackRock Discloses 15.6% Stake in Collegium Pharmaceutical
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 15.6% in Collegium Pharmaceutical, Inc. as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 4,997,827 shares of Common Stock in Collegium Pharmaceutical, Inc.
- This represents 15.6% of Collegium Pharmaceutical, Inc.'s total outstanding common stock.
- BlackRock holds sole voting power over 4,950,130 shares and sole dispositive power over 4,997,827 shares.
- The filing is an Amendment No. 8 to a Schedule 13G, indicating a series of previous filings by BlackRock regarding its stake in Collegium.
- One of BlackRock's subsidiaries, iShares Core S&P Small-Cap ETF, is identified as holding more than 5% of the total outstanding common stock of Collegium Pharmaceutical, Inc.
- BlackRock Fund Advisors is also noted as an entity that beneficially owns 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing disclosing beneficial ownership, providing factual information without expressing explicit sentiment regarding the issuer's performance or outlook. The large stake by BlackRock could be seen as a positive signal, but the filing itself is neutral.
Positives
- Increased transparency regarding significant institutional ownership in Collegium Pharmaceutical, Inc.
- BlackRock's substantial stake (15.6%) could be interpreted as a vote of confidence in Collegium Pharmaceutical, Inc. by a major institutional investor.
Risks
- No specific risks related to Collegium Pharmaceutical, Inc.'s operations or financial health are disclosed in this ownership filing, as it pertains solely to beneficial ownership.
Future Outlook
This Schedule 13G filing is a disclosure of current beneficial ownership and does not contain any forward-looking statements or guidance regarding Collegium Pharmaceutical, Inc.'s future performance or BlackRock's future investment intentions beyond its passive holding status.
Industry Context
Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% of a company's voting stock, indicating a passive investment intent. BlackRock, as one of the world's largest asset managers, frequently files such reports across numerous companies, reflecting its broad portfolio management activities. This filing provides transparency into its significant, but passive, stake in Collegium Pharmaceutical, Inc., a company operating in the pharmaceutical sector.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Power of Attorney Update | BlackRock, Inc. executed a new Power of Attorney, effective January 21, 2025, which revokes a previous Power of Attorney dated April 30, 2023. This new document grants specific individuals the authority to execute and file various ownership and control-person reporting requirements on behalf of BlackRock and its subsidiaries. | 01/21/2025 | Enhances internal governance and efficiency for BlackRock's regulatory filing processes, ensuring compliance with SEC and other governmental reporting requirements for its extensive investment holdings. |
Stakeholder Impact
- Shareholders of Collegium Pharmaceutical, Inc.: Provides transparency regarding a significant institutional shareholder's stake, which can influence market perception and liquidity.
- Investors in BlackRock funds: Offers insight into BlackRock's portfolio composition and its passive investment strategies.
Key Dates
| Date | Description |
|---|---|
| 04/30/2023 | Date of previous Power of Attorney that was revoked by BlackRock. |
| 01/21/2025 | Date of the new Power of Attorney executed by BlackRock, Inc. |
| 03/31/2025 | Date of event which required the filing of this statement (reporting period end date for beneficial ownership). |
| 04/28/2025 | Date the Schedule 13G Amendment No. 8 was signed by BlackRock, Inc. |
Keywords
BlackRock, Collegium Pharmaceutical, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Pharmaceutical, Investment Management, iShares Core S&P Small-Cap ETF
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.